公开(公告)号：US20140377215A1

公开(公告)日：2014-12-25

申请号：US14365226

申请日：2012-12-14

Applicant: The Board of Turstees of the University of Arkansas ,  KITASATO UNIVERSITY ,  MONTEFIORE MEDICAL CENTER

Inventor： Tulasi Ponnapakkam ,  Sagaya Theresa Leena Philominathan ,  Joshua Sakon ,  Ranjitha Katikaneni ,  Takaki Koide ,  Osamu Matsushita ,  Robert C. Gensure

IPC: A61K8/66 ,  A61K39/44 ,  A61K47/48 ,  A61Q7/00 ,  A61K38/29 ,  A61K38/18 ,  A61K38/30 ,  A61K38/17 ,  A61K8/64 ,  A61K38/19 ,  A61Q7/02

CPC classification number: C12N9/52 ,  A61K8/4913 ,  A61K8/64 ,  A61K8/65 ,  A61K8/66 ,  A61K8/99 ,  A61K38/00 ,  A61K38/179 ,  A61K38/18 ,  A61K38/1808 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/1858 ,  A61K38/1866 ,  A61K38/1875 ,  A61K38/193 ,  A61K38/27 ,  A61K38/29 ,  A61K38/30 ,  A61K39/3955 ,  A61K39/44 ,  A61K47/64 ,  A61K2039/505 ,  A61K2039/6031 ,  A61K2800/57 ,  A61Q7/00 ,  A61Q7/02 ,  C07K14/475 ,  C07K14/485 ,  C07K14/49 ,  C07K14/495 ,  C07K14/50 ,  C07K14/51 ,  C07K14/535 ,  C07K14/61 ,  C07K14/71 ,  C07K16/18 ,  C07K2319/31 ,  C07K2319/70 ,  C07K2319/74 ,  C12Y304/24003

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract translation: 提供了通过将包含与治疗剂连接的细菌胶原结合多肽片段的组合物施用于需要用治疗剂治疗的受试者来递送治疗剂的方法。 在这些方法中，治疗剂不是PTH / PTHrP受体激动剂或拮抗剂，碱性成纤维细胞生长因子（bFGF）或表皮生长因子（EGF）。 细菌胶原结合多肽片段将药物递送到部分未扭曲或扭曲不足的胶原蛋白部位。 还提供了使用包含胶原结合多肽和PTH / PTHrP受体激动剂的组合物治疗胶原病的方法。 此外，提供使用包含胶原结合多肽和PTH / PTHrP受体激动剂的组合物治疗甲状旁腺机能亢进和脱发的方法。 最后，提供通过施用包含胶原结合多肽和PTH / PTHrP受体拮抗剂的组合物来减少头发再生的方法。

公开(公告)号：US20140370035A1

公开(公告)日：2014-12-18

申请号：US14371931

申请日：2013-01-12

Applicant: Biogen Idec MA Inc. ,  Puget Sound Blood Center

Inventor： Haiyan Jiang ,  Tongyao Liu ,  Sriram Krishnamoorthy ,  Neil Josephson ,  Glenn Pierce

IPC: A61K47/48 ,  C12Q1/68 ,  A61K38/37

CPC classification number: C12Q1/6883 ,  A61K38/21 ,  A61K38/37 ,  A61K39/0008 ,  A61K47/6811 ,  A61K47/6815 ,  A61K2039/6031 ,  A61K2039/6056 ,  C07K14/755 ,  C07K2319/30 ,  C12Q2600/156 ,  A61K2300/00

Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Abstract translation: 本公开提供了将具有FVIII和Fc的嵌合和杂合因子VIII（FVIII）多肽施用于具有发展抑制性FVIII免疫应答风险的受试者的方法，所述风险包括抗FVIII抗体和/或细胞介导的免疫。 该施用足以促进凝血并诱导对FVIII的免疫耐受。 嵌合多肽可以包含全长FVIII或含有缺失的FVIII多肽，例如B结构域的完整或部分缺失。

公开(公告)号：US08912311B2

公开(公告)日：2014-12-16

申请号：US13864096

申请日：2013-04-16

Applicant: Københavns Universitet ,  Cancer Research Technology Limited

Inventor： Henrik Clausen ,  Joy Burchell ,  Ulla Mandel ,  Anne Louise Sørensen ,  Mads Agervig Tarp ,  Joyce Taylor-Papadimitriou

IPC: C07K16/00 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  G01N33/68 ,  A61K47/48 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/0011 ,  A61K47/646 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6075 ,  A61K2039/6081 ,  C07K14/4727 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3092 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C40B30/04 ,  C40B50/06 ,  G01N33/574 ,  G01N33/6854 ,  Y02A50/412

Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.

Abstract translation: 本发明提供使用免疫原性糖肽诱导针对MUC1的癌症特异性免疫应答的方法。 本发明的其它方面是包含免疫原性糖肽和包含免疫原性糖肽的癌症疫苗的药物组合物。 另一方面是使用免疫原性糖肽产生的抗体和所述抗体在治疗和诊断中的用途。

公开(公告)号：US08895724B2

公开(公告)日：2014-11-25

申请号：US12887636

申请日：2010-09-22

Applicant: William P. Hausdorff ,  George Rainer Siber ,  Peter R. Paradiso ,  A. Krishna Prasad

Inventor： William P. Hausdorff ,  George Rainer Siber ,  Peter R. Paradiso ,  A. Krishna Prasad

IPC: C07B37/00 ,  A61K39/09 ,  A61K39/00

CPC classification number: A61K39/092 ,  A61K39/385 ,  A61K2039/6031 ,  A61K2039/6037

Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 1 polysaccharide covalently linked to a carrier protein, the method including partial de-O-acetylation of the polysaccharide by mild hydrolysis in an alkaline pH buffer.

Abstract translation: 描述了具有13种不同的多糖 - 蛋白质缀合物和任选的基于铝的佐剂的免疫原性组合物。 每个缀合物含有由与载体蛋白缀合的不同血清型肺炎链球菌（1,3,4,5,6A，6B，7F，9V，14,18C，19A，19F和23F）制备的荚膜多糖。 配制成疫苗的免疫原性组合增加了全球婴儿和幼儿肺炎球菌病的覆盖率，并为不依赖于血清群交叉保护的限制的血清型6A和19A提供了覆盖。 还描述了一种用于制备包含与载体蛋白共价连接的肺炎链球菌血清型1多糖的免疫原性缀合物的方法，该方法包括在碱性pH缓冲液中通过轻度水解部分脱-O-乙酰化多糖。

公开(公告)号：US20140341943A1

公开(公告)日：2014-11-20

申请号：US14301931

申请日：2014-06-11

Applicant: The Ohio State University Research Foundation

Inventor： Yasuko Rikihisa

IPC: C07K7/08 ,  G01N33/569

CPC classification number: A61K39/0233 ,  A61K38/00 ,  A61K38/04 ,  A61K2039/552 ,  A61K2039/575 ,  A61K2039/6031 ,  C07K7/08 ,  C07K14/29 ,  G01N33/53 ,  G01N33/56911 ,  G01N33/6854 ,  G01N2333/29 ,  G01N2469/20 ,  Y02A50/402

Abstract: The novel omp-1 gene cluster encoding twenty one Ehrlichia ewingii (EE) proteins was isolated and sequenced completely. This invention relates to isolated E. ewingii (EE) polypeptides, isolated polynucleotides encoding EE polypeptides, probes, primers, isolated antibodies and methods of their production, immunogenic compositions and vaccines, as well as methods of using the EE polypeptides, antibodies, probes, and primers for the purpose of diagnosis, therapy and production of vaccines against E. ewingii.

Abstract translation: 分离编码二十一种Ehilichia ewingii（EE）蛋白质的新型omp-1基因簇，并完全测序。 本发明涉及分离的E.Ewingii（EE）多肽，编码EE多肽的分离的多核苷酸，探针，引物，分离的抗体及其生产方法，免疫原性组合物和疫苗，以及使用EE多肽，抗体，探针， 和引物，用于诊断，治疗和生产针对大肠埃希氏芽孢杆菌的疫苗。

公开(公告)号：US20140328851A1

公开(公告)日：2014-11-06

申请号：US14279182

申请日：2014-05-15

Applicant: The Regents of the University of California

Inventor： Gang Ren ,  Lei Zhang

IPC: C07K16/18 ,  A61K49/00

CPC classification number: C07K16/18 ,  A61K39/0005 ,  A61K49/0004 ,  A61K2039/6031 ,  C07K2317/76 ,  Y02A50/466

Abstract: Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy.

Abstract translation: 本文描述了可抑制CETP-脂蛋白相互作用和CETP活性的两种抗体。 目前描述的是能够特异性结合CETP的N末端或C末端结构域的抗体或其片段的抗体或其片段，以及使用这些抗体进行分离，鉴定，诊断和治疗的方法。

公开(公告)号：US20140322301A1

公开(公告)日：2014-10-30

申请号：US14256091

申请日：2014-04-18

Applicant: MicroVAX, LLC

Inventor： Yucheng Tang ,  Albert Deisseroth

IPC: A61K48/00 ,  A61K9/127 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K9/127 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/6031 ,  C07K14/4727 ,  C07K14/70578 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10043

Abstract: Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

公开(公告)号：US20140286983A1

公开(公告)日：2014-09-25

申请号：US14352812

申请日：2012-10-18

Applicant: The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services

Inventor： Gwong-Jen J. Chang ,  Wayne D. Crill ,  Holly R. Hughes ,  Brent S. Davis

IPC: C07K14/005 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/6075 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/24122 ,  C12N2770/24123 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24171 ,  Y02A50/386

Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.

Abstract translation: 本文描述的是具有消除与免疫增强相关的免疫优势交叉反应性表位的突变的登革病毒E-糖蛋白多肽。 所公开的登革热病毒E-糖蛋白任选地还包括引入强CD4T细胞表位的突变。 公开的E-糖蛋白多肽或编码多肽的核酸分子可用于例如针对登革热病毒的单价或四价疫苗。

公开(公告)号：US08828957B2

公开(公告)日：2014-09-09

申请号：US11009533

申请日：2004-12-10

Applicant: Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

Inventor： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

IPC: A61K48/00 ,  A61K38/00

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K2039/545 ,  A61K2039/6031 ,  C07K14/70578 ,  C12N15/86 ,  C12N2710/10343

Abstract: Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

Abstract translation: 提供了产生对抗原的免疫应答的方法。 该方法包括通过施用编码抗原的表达载体来引发个体。 载体包含编码可分泌融合蛋白的转录单元，含有抗原和CD40配体的融合蛋白。 使用含有抗原和CD40配体的融合蛋白的施用用于增强仅通过单独载体给药获得的免疫应答。 本发明的方法可用于产生针对表达肿瘤抗原例如粘蛋白或人乳头状瘤病毒肿瘤抗原的癌症的免疫应答，并产生针对感染因子的免疫应答。 还提供了同时产生表达载体和融合蛋白的方法。

公开(公告)号：US20140234356A1

公开(公告)日：2014-08-21

申请号：US14139293

申请日：2013-12-23

Applicant: Immune Targeting Systems Ltd.

Inventor： Dominique Bonnet ,  Carlton B. Brown ,  Bertrand Victor Gilbert Georges ,  Philip J. Sizer

IPC: A61K47/48 ,  A61K39/145

CPC classification number: A61K47/4833 ,  A61K39/12 ,  A61K39/145 ,  A61K39/21 ,  A61K39/385 ,  A61K47/54 ,  A61K47/58 ,  A61K47/646 ,  A61K2039/54 ,  A61K2039/55511 ,  A61K2039/60 ,  A61K2039/6018 ,  A61K2039/6031 ,  C07K14/005 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16034 ,  C12N2760/16122 ,  C12N2760/16222 ,  C12N2760/16322

Abstract: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.

Abstract translation: 本发明涉及用于将流感抗原递送至免疫反应性靶细胞的碳氟载体。 它进一步涉及氟碳载体 - 流感抗原构建体，以及在动物（包括人）中使用与抗原相关的载体作为疫苗和免疫治疗剂。